Jane Street’s Taysha Gene Therapies TSHA Stock Holding History

Jane Street’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Buy	+228,355	New	+$1.35M	﹤0.01%	5622
2026 Q1	–	Sell	-163,146	Closed	-$759K	–	13011
2025 Q4	$897K	Sell	163,146 -393,639	-71%	-$1.91M	﹤0.01%	6345
2025 Q3	$1.82M	Buy	556,785 +419,791	+306%	+$1.19M	﹤0.01%	5109
2025 Q2	$316K	Buy	+136,994	New	+$298K	﹤0.01%	7763
2025 Q1	–	Sell	-169,575	Closed	-$293K	–	10630
2024 Q4	$293K	Buy	169,575 +62,003	+58%	+$129K	﹤0.01%	7774
2024 Q3	$216K	Sell	107,572 -20,552	-16%	-$45.1K	﹤0.01%	8545
2024 Q2	$287K	Buy	128,124 +69,238	+118%	+$201K	﹤0.01%	7871
2024 Q1	$169K	Buy	58,886 +16,608	+39%	+$34.6K	﹤0.01%	8274
2023 Q4	$74.8K	Buy	+42,278	New	+$84.3K	﹤0.01%	8680
2020 Q4	–	Sell	-23,234	Closed	-$520K	–	8118
2020 Q3	$520K	Buy	+23,234	New	+$547K	﹤0.01%	5089

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's TSHA Position: Q2 2026 in Review

Jane Street opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 228,355 shares worth $1.56M. The stake represents ﹤0.01% of the portfolio and ranks #5622 among its holdings. This is a return to the name: Jane Street previously reported a position in TSHA as recently as Q4 2025.

Jane Street first reported a position in TSHA in Q3 2020 and has held it in 10 quarters since. The position peaked at $1.82M in Q3 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Jane Street held 228,355 shares of Taysha Gene Therapies worth $1.56M as of Q2 2026.
Taysha Gene Therapies was a new Jane Street position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5622 holding.
Jane Street first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 10 quarters since.
Jane Street's Taysha Gene Therapies position peaked at $1.82M in Q3 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.